Placement to accelerate NNZ-2591 across 4 indications
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- FDA grants Orphan Drug designation for Prader-Willi syndrome
- Angelman IND and Ethics applications submitted for NNZ-2591
- R&D Tax Incentive Advance Overseas Finding Approval
- Phase 3 enrolment successfully completed, results in Q4 2021
- Q2 2021 quarterly activity and cash flow report
Later from Neuren Pharmaceuticals
- Investor Presentation, 13 September 2021
- New patent issued to 2032 for Neurens trofinetide in Brazil
- Share Purchase Plan Offer Booklet
- IND application submitted for NNZ-2591 in Phelan-McDermid
- Feedback on Angelman IND and submission of Pitt Hopkins IND
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals